Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The site’s footer revision changed from v3.7.0 to v3.7.1, and a feedback tab is visible along the page edge.
    Difference
    0.2%
    Check dated 2026-10-06T22:04:26.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error page with a Home link, replacing the usual content and preventing access to the trial's details. This change removes the expected study information from the page and directs users to the site’s home page instead.
    Difference
    22%
    Check dated 2026-09-22T23:29:09.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A new site revision label, v3.7.0, was added while the previous label, v3.6.6, was removed, indicating an internal build update rather than changes to the study record.
    Difference
    0.0%
    Check dated 2026-09-15T22:27:50.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.6, replacing the previous v3.6.5. This indicates a maintenance/update to the page's underlying system rather than changes to the study content.
    Difference
    0.0%
    Check dated 2026-09-01T18:14:00.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    A 2023 U.S. NIH Grant/Contract funding line was added to the study's funding disclosures, updating the source of support for the trial.
    Difference
    0.0%
    Check dated 2026-08-25T19:00:54.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Tumor size change definitions were added to specify that change is the best percent change from baseline in the sum of target lesions, assessed by centralized review (BICR) per RECIST 1.1, and the mean of this metric is presented. The EORTC QLQ-C30 quality-of-life description was expanded to explain scoring and interpretation (7-point scale and 0–100 normalization), and the Plain Language Summary was removed.
    Difference
    0.3%
    Check dated 2026-08-18T15:59:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.